TY - JOUR
T1 - Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
AU - Saidha, Shiv
AU - Bell, Judith
AU - Harold, Sydney
AU - Belisario, Jose Marcano
AU - Hawe, Emma
AU - Shao, Qiujun
AU - Wyse, Kerri
AU - Maiese, Eric M.
N1 - Funding Information:
This study was funded by Novartis Pharmaceuticals Corporation. Medical writing support for manuscript development was provided by Kate Lothman, BA, of RTI Health Solutions, and infographic development support was provided by Julie Wilkinson, PhD, and Nancy Nguyen, PharmD, of Envision Pharma Group; funded by Novartis Pharmaceuticals Corporation. This manuscript was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this article.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/5
Y1 - 2023/5
N2 - Objective: To explore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the relationship between Ig levels and infections. Methods: A systematic literature review (SLR) was conducted to identify clinical trials and real-world evidence (RWE) studies on Ig levels over time and studies on associations with infections for ocrelizumab and ofatumumab for people with RMS through 10 September 2021. Searches were conducted in Embase, MEDLINE, Cochrane Library, trial registries, and recent conference abstracts. Results: Of 1,580 articles identified, 30 reporting on 11 trials and 5 RWE studies were included. Ocrelizumab trials (n = 4) had 24–336 weeks of follow-up and reported decreasing Ig G (IgG) levels, while RWE (n = 5) had 52–78 weeks of follow-up and reported IgG to be stable or decrease only slightly. IgG levels were stable in ofatumumab trials (n = 5; 104–168 weeks of follow-up), but no RWE or longer-term studies were identified. No apparent association between decreased Ig levels and infections was observed during ofatumumab treatment (ASCLEPIOS I/II), while for ocrelizumab, the only data on apparent associations between decreased IgG levels and serious infection rates were for a pooled population of people with RMS or primary progressive MS. Conclusion: Decreasing IgG levels have been correlated with increased infection risk over time. IgG levels appeared to decrease over time in ocrelizumab trials but remained relatively stable over time in ofatumumab trials. Additional research is needed to understand differences between ocrelizumab and ofatumumab and identify people at risk of decreasing IgG levels and infection.
AB - Objective: To explore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the relationship between Ig levels and infections. Methods: A systematic literature review (SLR) was conducted to identify clinical trials and real-world evidence (RWE) studies on Ig levels over time and studies on associations with infections for ocrelizumab and ofatumumab for people with RMS through 10 September 2021. Searches were conducted in Embase, MEDLINE, Cochrane Library, trial registries, and recent conference abstracts. Results: Of 1,580 articles identified, 30 reporting on 11 trials and 5 RWE studies were included. Ocrelizumab trials (n = 4) had 24–336 weeks of follow-up and reported decreasing Ig G (IgG) levels, while RWE (n = 5) had 52–78 weeks of follow-up and reported IgG to be stable or decrease only slightly. IgG levels were stable in ofatumumab trials (n = 5; 104–168 weeks of follow-up), but no RWE or longer-term studies were identified. No apparent association between decreased Ig levels and infections was observed during ofatumumab treatment (ASCLEPIOS I/II), while for ocrelizumab, the only data on apparent associations between decreased IgG levels and serious infection rates were for a pooled population of people with RMS or primary progressive MS. Conclusion: Decreasing IgG levels have been correlated with increased infection risk over time. IgG levels appeared to decrease over time in ocrelizumab trials but remained relatively stable over time in ofatumumab trials. Additional research is needed to understand differences between ocrelizumab and ofatumumab and identify people at risk of decreasing IgG levels and infection.
KW - Anti-CD20 monoclonal antibodies
KW - Immunoglobulin
KW - Infection
KW - Multiple Sclerosis
KW - Systematic literature review
UR - http://www.scopus.com/inward/record.url?scp=85146384335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146384335&partnerID=8YFLogxK
U2 - 10.1007/s10072-022-06582-y
DO - 10.1007/s10072-022-06582-y
M3 - Review article
C2 - 36648561
AN - SCOPUS:85146384335
SN - 1590-1874
VL - 44
SP - 1515
EP - 1532
JO - Neurological Sciences
JF - Neurological Sciences
IS - 5
ER -